Phase I study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukaemia: maintaining immune functions during therapy-induced immunosuppression

Br J Haematol. 2012 Dec;159(5):608-12. doi: 10.1111/bjh.12077. Epub 2012 Oct 9.

Authors

Sandra Eketorp Sylvan, Eva Rossmann, Fariba Mozaffari, Anna Porwit, Stefan Norin, Claes Karlsson, Lotta Hansson, Jeanette Lundin, Anders Österborg

PMID: 23043283
DOI: 10.1111/bjh.12077

No abstract available

Publication types

Clinical Trial, Phase I
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Alemtuzumab
Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / adverse effects
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Female
Humans
Immunosuppression Therapy / methods
Lenalidomide
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Leukemia, Lymphocytic, Chronic, B-Cell / immunology*
Male
Thalidomide / administration & dosage
Thalidomide / adverse effects
Thalidomide / analogs & derivatives

Substances

Antibodies, Monoclonal, Humanized
Alemtuzumab
Thalidomide
Lenalidomide